Table 2.
Clinical trials of venetoclax-included combination therapy in CLL and B-cell malignancies
| Agents combined with venetoclax | Disease | Phase | Estimated number of patients | Status | ClinicalTrial.gov ID |
|---|---|---|---|---|---|
| Rituximab | R/R CLL | Ib | 49 | Ref 62 | NCT01682616 |
| Ibrutinib | CLL; R/R or high risk, treatment-naïve | II | 78 | Recruiting | NCT02756897 |
| Ibrutinib, obinutuzumab | Treatment-naïve CLL; with TP53 deletion and/or mutation | II | 40 | Recruiting | NCT02758665 |
| Ibrutinib | Treatment-naïve CLL | II | 150 | Recruiting | NCT02910583 |
| Rituximab or obinutuzumab obinutuzumab + ibrutinib (vs FCR/BR w/0 venetoclax) | Fit treatment-naïve CLL without del (17p) or TP53 mutation | III | 920 | Recruiting | NCT02950051 |
| BR or BG | CLL; R/R or Treatment-naïve | I | 100 | Recruiting | NCT01671904 |
| Obinutuzumab, ibrutinib | CLL; R/R or Treatment-naïve | I/II | 68 | Ref 71 | NCT02427451 |
| Obinutuzumab | Treatment-naïve FL | I | 25 | Planned | NCT02877550 |
| BR or rituximab (vs BR without venetoclax) | R/R FL | II | 165 | Interim data, ref 63 | NCT02187861 |
| Ibrutinib | R/R FL | I/II | 41 | Recruiting | NCT02956382 |
| Obinutuzumab, polatuzumab vedotin (ADC against CD79b) | R/R FL or DLBCL | Ib/II | 119 | Recruiting | NCT02611323 |
| Ibrutinib | R/R MCL | I/IB | 28 | Recruiting | NCT02419560 |
| Obinutuzumab, Lenalidomide | R/R B-cell NHL | I | 60 | Planned | NCT02992522 |
| DA-EPOCH plus rituximab | Aggressive B-cell lymphoma | I | 18 | Planned | NCT03036904 |
| Obinutuzumab, | R/R DLBCL | II | 21 | Planned | NCT02987400 |
| Dexamethasone; carfilzomib | R/R MM | II | 40 | Recruiting | NCT02899052 |
| ABBV-838 (ADC against CS-1); Dexamethasone | R/R MM | IB | 72 | Planned | NCT02951117 |
| Bortezomib + Dex (vs Bortezomib + Dex + placebo) | R/R MM | III | 240 | Recruiting | NCT02755597 |
Abbreviations: ADC, antibody-drug conjugate; R/R, relapsed/refractory; CLL, chronic lymphocytic leukemia; FCR, fludarabine, cyclophosphamide, rituximab; BR, bendamustine plus rituximab; BG, bendamustine plus obinutuzumab; MCL, mantle cell lymphoma; DLBCL, diffuse large B-cell lymphoma; DA-EPOCH, dose-adjusted doxorubicin hydrochloride, etoposide, vincristine sulfate, cyclophosphamide, prednisone; Dex, dexamethasone; MM, multiple myeloma.